OncoZenge AB (FRA:8LY) ROE % Adjusted to Book Value : -20.06% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB ROE % Adjusted to Book Value?

OncoZenge AB's ROE % for the quarter that ended in Dec. 2024 was -88.48%. OncoZenge AB's PB Ratio for the quarter that ended in Dec. 2024 was 4.41. OncoZenge AB's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -20.06%.

OncoZenge AB ROE % Adjusted to Book Value Historical Data

The historical data trend for OncoZenge AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB ROE % Adjusted to Book Value Chart

OncoZenge AB Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

-4.21

-43.69

-33.98

-13.53

OncoZenge AB Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial												-37.44	-23.04	-22.32	-8.82	-20.06

Competitive Comparison of OncoZenge AB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, OncoZenge AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoZenge AB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoZenge AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where OncoZenge AB's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

OncoZenge AB ROE % Adjusted to Book Value Calculation

OncoZenge AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-59.66%	/	4.41
	=	-13.53%

OncoZenge AB's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-88.48%	/	4.41
	=	-20.06%

OncoZenge AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoZenge AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (FRA:8LY) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ONCOZ:Sweden

Address

Gustavslundsvagen 34, Bromma, SWE, 167 51

Website

https://www.oncozenge.com

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines